A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain,
may be a valuable tool in the early detection, understanding, or evaluation of Parkinson
disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum
Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).
The goal of this study is to assess [18F]F-PEB positron emission tomography (PET) imaging as
a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research
participants and similarly aged healthy subjects.